<DOC>
	<DOCNO>NCT01313559</DOCNO>
	<brief_summary>This open label randomize phase II study prostate cancer patient disease progression hormonal therapy . SOM230 LAR ( Pasireotide ) bind receptor prostate cancer cell prevent grow . Everolimus work target cell survival factor prostate cancer . The combination drug may work well treatment prostate cancer without toxic chemotherapy . Patients receive either SOM230 LAR ( group A ) SOM230 LAR combination Everolimus ( group B ) .</brief_summary>
	<brief_title>Pasireotide ( SOM230 ) With Without Everolimus Treating Patients With Hormone Resistant , Chemotherapy Naive Prostate Cancer</brief_title>
	<detailed_description>Prostate cancer cell typically neuroendocrine ( NE ) differentiation feature become resistant hormonal therapy . Somatostatin ( SST - peptide hormone ) receptor ( SSTR ) usually express high level advance prostate cancer cell . When SSTR activate pharmacologically drug similar SST , prostate cancer cell growth inhibit . SOM230 new agent activate SSTR block key survival molecules/pathways phosphatidylinositol 3-kinases ( PI3K ) , mitogen-activated protein ( MAP ) kinases ( MAPK ) signal pathway . Thus SOM230 anticancer activity prostate cancer . It also well know hormonal refractory prostate cancer grow environment low male hormone level activation several non-androgen receptor survival pathway . One key survival pathway mediate important molecule call mammalian target rapamycin ( mTOR ) . Drugs , Everolimus , anticancer activity prostate cancer pre-clinically , sustain activity . The reason cancer cell up-regulate survival pathway PI3K , MAPK , thus bypass mTOR . It hypothesize SOM230 anti-tumor effect prostate cancer directly , also block up-regulated ( feed-back loop ) , alternative PI3K MAPK survival pathway induce mTOR inhibitor . The goal study develop new well tolerate therapy offer prostate cancer patient prior receive chemotherapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Age minimum : 18 year old Histological confirmation prostatic adenocarcinoma PSA &gt; = 2 ng/ml PSA progression ( serially rise two occasion least one week apart ) OR disease progression image study ( CT scan bone scan ) . Minimally symptomatic symptom attribute prostate cancer great Grade I base NCI CTCAE Version 4.0 grade toxicity Discontinuation antiandrogen , ketoconazole investigational drug least 4 week ( 6 week bicalutamide ) prior study initiation Maintain castrate level testosterone ( &lt; 50ng/dL ) Karnofsky Performance Status &gt; = 60 % Life expectancy &gt; 3 month Adequate hematologic , renal , liver function Currently active second malignancy nonmelanoma skin cancer . Clinically significant cardiovascular disease : EF &lt; 30 % , NHYA Class III great congestive heart failure , myocardial infarction/unstable angina within 6 month prior study enrollment , significant ECG abnormality QRS/QT prolongation ( see Section 5.3 ) . Progressive pulmonary disease , advance COPD , pulmonary fibrosis , supplemental O2 requirement . Known CNS disease , except treat brain metastasis . Poorly control diabetes mellitus ( HbA1c &gt; 7 % ) fasting blood glucose level &gt; 126 mg/dL nondiabetic patient &gt; 189 mg/dL diabetic patient ( enrolled initiation titration antidiabetic agent ( ) ) . Poorly control hypercholesterolemia ( fast serum cholesterol &gt; 300 mg/dL ) hypertriglyceridemia ( &gt; 2.5 x ULN ) . Patients either threshold included initiation appropriate lipid lower medication . Current use chronic steroid ( equivalent 20mg prednisone daily ) . Inhaled steroid acceptable . Active gallbladder disease hepatitis ( AST ALT &gt; 2.0 , bilirubin &gt; 1.5x ULN ) , liver cirrhosis , severe liver impairment ( ChildPugh class C ) . It highly recommend patient positive HBVDNA HBsAg treat prophylactically antiviral 12 week prior receive study drug . Serum creatinine &gt; 1.5 upper limit normal dialysis . Prior use somatostatin analog mTOR inhibitor treatment PC .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Castrate Resistant</keyword>
	<keyword>Chemotherapy Naive</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>SOM230</keyword>
	<keyword>Everolimus</keyword>
</DOC>